379 related articles for article (PubMed ID: 25175600)
41. Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G.
Zhou J; Johnson JE; Ghetie V; Ober RJ; Ward ES
J Mol Biol; 2003 Sep; 332(4):901-13. PubMed ID: 12972260
[TBL] [Abstract][Full Text] [Related]
42. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
[TBL] [Abstract][Full Text] [Related]
43. V Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc Receptor.
Rossini S; Noé R; Daventure V; Lecerf M; Justesen S; Dimitrov JD
J Immunol; 2020 Nov; 205(10):2850-2860. PubMed ID: 33077645
[TBL] [Abstract][Full Text] [Related]
44. Fc engineering: serum half-life modulation through FcRn binding.
Olafsen T
Methods Mol Biol; 2012; 907():537-56. PubMed ID: 22907373
[TBL] [Abstract][Full Text] [Related]
45. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
46. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.
Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H
MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930
[TBL] [Abstract][Full Text] [Related]
47. A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life.
Jensen PF; Schoch A; Larraillet V; Hilger M; Schlothauer T; Emrich T; Rand KD
Mol Cell Proteomics; 2017 Mar; 16(3):451-456. PubMed ID: 28062799
[TBL] [Abstract][Full Text] [Related]
48. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.
Ying T; Chen W; Feng Y; Wang Y; Gong R; Dimitrov DS
J Biol Chem; 2013 Aug; 288(35):25154-25164. PubMed ID: 23867459
[TBL] [Abstract][Full Text] [Related]
49. Computational determination of the structure of rat Fc bound to the neonatal Fc receptor.
Weng Z; Gulukota K; Vaughn DE; Bjorkman PJ; DeLisi C
J Mol Biol; 1998 Sep; 282(2):217-25. PubMed ID: 9735282
[TBL] [Abstract][Full Text] [Related]
50. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand.
Sánchez LM; Penny DM; Bjorkman PJ
Biochemistry; 1999 Jul; 38(29):9471-6. PubMed ID: 10413524
[TBL] [Abstract][Full Text] [Related]
51. IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.
Ternant D; Arnoult C; Pugnière M; Dhommée C; Drocourt D; Perouzel E; Passot C; Baroukh N; Mulleman D; Tiraby G; Watier H; Paintaud G; Gouilleux-Gruart V
J Immunol; 2016 Jan; 196(2):607-13. PubMed ID: 26685205
[TBL] [Abstract][Full Text] [Related]
52. Structural insights into neonatal Fc receptor-based recycling mechanisms.
Oganesyan V; Damschroder MM; Cook KE; Li Q; Gao C; Wu H; Dall'Acqua WF
J Biol Chem; 2014 Mar; 289(11):7812-24. PubMed ID: 24469444
[TBL] [Abstract][Full Text] [Related]
53. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants.
Raghavan M; Bonagura VR; Morrison SL; Bjorkman PJ
Biochemistry; 1995 Nov; 34(45):14649-57. PubMed ID: 7578107
[TBL] [Abstract][Full Text] [Related]
54. Development and applications of AlphaScreen-based FcRn binding assay to characterize monoclonal antibodies.
Wu Q; Lee HY; Wong PY; Jiang G; Gazzano-Santoro H
J Immunol Methods; 2015 May; 420():31-7. PubMed ID: 25837414
[TBL] [Abstract][Full Text] [Related]
55. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry.
Jensen PF; Larraillet V; Schlothauer T; Kettenberger H; Hilger M; Rand KD
Mol Cell Proteomics; 2015 Jan; 14(1):148-61. PubMed ID: 25378534
[TBL] [Abstract][Full Text] [Related]
56. Albumin binding to FcRn: distinct from the FcRn-IgG interaction.
Chaudhury C; Brooks CL; Carter DC; Robinson JM; Anderson CL
Biochemistry; 2006 Apr; 45(15):4983-90. PubMed ID: 16605266
[TBL] [Abstract][Full Text] [Related]
57. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells.
Goebl NA; Babbey CM; Datta-Mannan A; Witcher DR; Wroblewski VJ; Dunn KW
Mol Biol Cell; 2008 Dec; 19(12):5490-505. PubMed ID: 18843053
[TBL] [Abstract][Full Text] [Related]
58. Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis.
Zhou J; Mateos F; Ober RJ; Ward ES
J Mol Biol; 2005 Feb; 345(5):1071-81. PubMed ID: 15644205
[TBL] [Abstract][Full Text] [Related]
59. The multiple facets of FcRn in immunity.
Stapleton NM; Einarsdóttir HK; Stemerding AM; Vidarsson G
Immunol Rev; 2015 Nov; 268(1):253-68. PubMed ID: 26497526
[TBL] [Abstract][Full Text] [Related]
60. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
